These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

830 related articles for article (PubMed ID: 23307539)

  • 21. Duration of prior vancomycin therapy and subsequent daptomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
    Culshaw D; Lamp KC; Yoon MJ; Lodise TP
    Diagn Microbiol Infect Dis; 2015 Oct; 83(2):193-7. PubMed ID: 26184127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy.
    Falcone M; Russo A; Pompeo ME; Vena A; Marruncheddu L; Ciccaglioni A; Grossi P; Mancini C; Novelli A; Stefani S; Venditti M
    Int J Antimicrob Agents; 2012 Jan; 39(1):64-8. PubMed ID: 22047703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacoeconomic analysis of the treatment of methicillin-resistant Staphylococcus aureus with daptomycin or vancomycin].
    Rubio-Terrés C; Rubio-Rodríguez D; Majos N; Grau S
    Rev Esp Quimioter; 2012 Dec; 25(4):283-92. PubMed ID: 23303261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
    Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
    J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
    Fowler VG; Boucher HW; Corey GR; Abrutyn E; Karchmer AW; Rupp ME; Levine DP; Chambers HF; Tally FP; Vigliani GA; Cabell CH; Link AS; DeMeyer I; Filler SG; Zervos M; Cook P; Parsonnet J; Bernstein JM; Price CS; Forrest GN; Fätkenheuer G; Gareca M; Rehm SJ; Brodt HR; Tice A; Cosgrove SE;
    N Engl J Med; 2006 Aug; 355(7):653-65. PubMed ID: 16914701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective observational study comparing vancomycin versus daptomycin as initial therapy for Staphylococcus aureus infections.
    Jobson S; Moise PA; Eskandarian R
    Clin Ther; 2011 Oct; 33(10):1391-9. PubMed ID: 22015328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin.
    Mohan SS; McDermott BP; Cunha BA
    Heart Lung; 2005; 34(1):69-71. PubMed ID: 15647736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Daptomycin therapy in patients with bacteremia].
    Llinares P; Iribarren JA
    Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():17-25. PubMed ID: 22541971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Molecular Epidemiology and Reduced Susceptibility to Glycopeptides and Daptomycin on Outcomes of Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia.
    Lee HY; Chen CL; Liu SY; Yan YS; Chang CJ; Chiu CH
    PLoS One; 2015; 10(8):e0136171. PubMed ID: 26295150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates.
    Rehm SJ; Boucher H; Levine D; Campion M; Eisenstein BI; Vigliani GA; Corey GR; Abrutyn E
    J Antimicrob Chemother; 2008 Dec; 62(6):1413-21. PubMed ID: 18782781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparative activity of daptomycin against clinical isolates of methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci].
    Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; López F; Gómez M;
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):13-6. PubMed ID: 19406529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.
    Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL
    J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: a hospital-based retrospective study.
    Chang HJ; Hsu PC; Yang CC; Siu LK; Kuo AJ; Chia JH; Wu TL; Huang CT; Lee MH
    J Antimicrob Chemother; 2012 Mar; 67(3):736-41. PubMed ID: 22169187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients.
    Rojas L; Bunsow E; Muñoz P; Cercenado E; Rodríguez-Créixems M; Bouza E
    J Antimicrob Chemother; 2012 Jul; 67(7):1760-8. PubMed ID: 22556382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of clinical and microbiological treatment failure in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective cohort study in a region with low MRSA prevalence.
    Forstner C; Dungl C; Tobudic S; Mitteregger D; Lagler H; Burgmann H
    Clin Microbiol Infect; 2013 Jul; 19(7):E291-7. PubMed ID: 23490021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High MICs for Vancomycin and Daptomycin and Complicated Catheter-Related Bloodstream Infections with Methicillin-Sensitive Staphylococcus aureus.
    San-Juan R; Viedma E; Chaves F; Lalueza A; Fortún J; Loza E; Pujol M; Ardanuy C; Morales I; de Cueto M; Resino-Foz E; Morales-Cartagena A; Rico A; Romero MP; Orellana MÁ; López-Medrano F; Fernández-Ruiz M; Aguado JM
    Emerg Infect Dis; 2016 Jun; 22(6):1057-66. PubMed ID: 27192097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia.
    Moise PA; Sakoulas G; Forrest A; Schentag JJ
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2582-6. PubMed ID: 17452488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
    Davis SL; McKinnon PS; Hall LM; Delgado G; Rose W; Wilson RF; Rybak MJ
    Pharmacotherapy; 2007 Dec; 27(12):1611-8. PubMed ID: 18041881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.